York Pei

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1369031/publications.pdf

Version: 2024-02-01

74 papers	4,963 citations	109137 35 h-index	95083 68 g-index
75 all docs	75 docs citations	75 times ranked	4541 citing authors

#	Article	IF	Citations
1	Unified Criteria for Ultrasonographic Diagnosis of ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 205-212.	3.0	590
2	Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nature Medicine, 2013, 19, 488-493.	15.2	403
3	Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidneyÂdisease. Nature Materials, 2017, 16, 1112-1119.	13.3	225
4	Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Human Molecular Genetics, 2009, 18, 2328-2343.	1.4	208
5	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2018, 102, 832-844.	2.6	208
6	Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. Journal of the American Society of Nephrology: JASN, 2018, 29, 2593-2600.	3.0	173
7	Bilineal Disease and Trans-Heterozygotes in Autosomal Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2001, 68, 355-363.	2.6	146
8	Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 1164-1174.	3.0	129
9	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 746-753.	3.0	126
10	Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1861-1868.	3.0	123
11	Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nature Genetics, 2000, 25, 143-144.	9.4	116
12	A â€˜two-hitâ€™ model of cystogenesis in autosomal dominant polycystic kidney disease?. Trends in Molecular Medicine, 2001, 7, 151-156.	3.5	111
13	Family History of Renal Disease Severity Predicts the Mutated Gene in ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1833-1838.	3.0	110
14	Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. European Urology, 2016, 70, 85-90.	0.9	105
15	A RhoAâ€“YAPâ€“c-Myc signaling axis promotes the development of polycystic kidney disease. Genes and Development, 2018, 32, 781-793.	2.7	94
16	Risk factors for renal osteodystrophy: A multivariant analysis. Journal of Bone and Mineral Research, 1995, 10, 149-156.	3.1	90
17	Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nature Communications, 2018, 9, 1960.	5.8	90
18	Progressive Loss of Renal Function Is an Age-Dependent Heritable Trait in Type 1 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 755-762.	3.0	84

#	Article	IF	Citations
19	Diagnostic Approach in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1108-1114.	2.2	75
20	Polycystic Kidney Disease without an Apparent Family History. Journal of the American Society of Nephrology: JASN, 2017, 28, 2768-2776.	3.0	75
21	Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 790-799.	2.2	73
22	Incident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease: A Population and Family-Based Cohort Followed for 22 Years. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 710-717.	2.2	67
23	Diagnosis and Screening of Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 140-152.	0.6	63
24	Presence of De Novo Mutations in Autosomal Dominant Polycystic Kidney Disease Patients Without Family History. American Journal of Kidney Diseases, 2008, 52, 1042-1050.	2.1	62
25	Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 3404-3413.	3.0	60
26	Genetic Variation of DKK3 May Modify Renal Disease Severity in ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1510-1520.	3.0	59
27	A missense mutation in PKD1 attenuates the severity of renal disease. Kidney International, 2012, 81, 412-417.	2.6	54
28	Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine, 2019, 47, 436-445.	2.7	50
29	Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	0.6	45
30	Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2015, 10, e0144526.	1.1	43
31	Intrafamilial Variability of ADPKD. Kidney International Reports, 2019, 4, 995-1003.	0.4	42
32	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 420-435.	2.6	40
33	Practical Genetics for Autosomal Dominant Polycystic Kidney Disease. Nephron Clinical Practice, 2010, 118, c19-c30.	2.3	39
34	Recurrent fetal loss associated with bilineal inheritance of type 1 autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2002, 40, 16-20.	2.1	38
35	Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811774953.	0.6	38
36	Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimentalÂAlport syndrome. Kidney International, 2017, 91, 1347-1361.	2.6	37

#	Article	IF	Citations
37	Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 1453-1460.	0.4	33
38	Diagnosis of Autosomal-Dominant Polycystic Kidney Disease: An Integrated Approach. Seminars in Nephrology, 2010, 30, 356-365.	0.6	27
39	Characterization of the Intrarenal Renin-Angiotensin System in Experimental Alport Syndrome. American Journal of Pathology, 2015, 185, 1423-1435.	1.9	27
40	Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clinical Proteomics, 2016, 13, 16.	1.1	24
41	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). Urology, 2016, 89, 19-26.	0.5	23
42	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	2.1	23
43	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€"Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	2.1	21
44	Standardised Outcomes in Nephrologyâ€"Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	0.7	20
45	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	0.7	20
46	Nature and nurture on phenotypic variability of autosomal dominant polycystic kidney disease. Kidney International, 2005, 67, 1630-1631.	2.6	19
47	Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cellular Signalling, 2020, 73, 109704.	1.7	19
48	Molecular diagnosis of autosomal dominant polycystic kidney disease. Expert Review of Molecular Diagnostics, 2017, 17, 885-895.	1.5	17
49	Tackling Dialysis Burden around the World: A Global Challenge. Kidney Diseases (Basel, Switzerland), 2021, 7, 167-175.	1.2	17
50	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	2.1	16
51	Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets. Kidney International, 2020, 98, 116-132.	2.6	16
52	Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 374-383.	2.2	15
53	Evidence for Pathogenicity of Atypical Splice Mutations in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 442-449.	2.2	12
54	Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation. Scientific Reports, 2019, 9, 10996.	1.6	11

#	Article	IF	Citations
55	Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study. Kidney Medicine, 2019, 1, 366-375.	1.0	10
56	Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease. Advances in Nutrition, 2022, 13, 652-666.	2.9	10
57	Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants. Kidney Medicine, 2021, 3, 257-266.	1.0	9
58	Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 827-834.	2.2	8
59	Low Turnover Bone Disease in Dialysis Patients. Seminars in Dialysis, 1996, 9, 327-331.	0.7	7
60	Positive Predictive Values of International Classification of Diseases, 10th Revision Coding Algorithms to Identify Patients With Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2016, 3, 205435811667913.	0.6	7
61	Methodological issues in clinical trials of polycystic kidney disease: a focused review. Journal of Nephrology, 2017, 30, 363-371.	0.9	7
62	Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 261-263.	2.6	7
63	Molecular genetics of autosomal dominant polycystic kidney disease. Clinical and Investigative Medicine, 2003, 26, 252-8.	0.3	7
64	X-Linked Glomerulopathy Due to COL4A5 FounderÂVariant. American Journal of Kidney Diseases, 2018, 71, 441-445.	2.1	5
65	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	0.8	5
66	Diagnostic accuracy of administrative codes for autosomal dominant polycystic kidney disease in clinic patients with cystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 612-616.	1.4	3
67	Diagnosis of autosomal dominant polycystic kidney disease. Expert Opinion on Medical Diagnostics, 2008, 2, 763-772.	1.6	2
68	Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812094043.	0.6	2
69	LAMA2 and LOXL4 are candidate FSGS genes. BMC Nephrology, 2021, 22, 320.	0.8	2
70	Does elevated urinary Dkkopf-3 level predict vulnerability to kidney injury during cardiac surgery?. Annals of Translational Medicine, 2019, 7, S296-S296.	0.7	0
71	Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations. Kidney International Reports, 2020, 5, 1828-1832.	0.4	0
72	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. , 2018, , 133-142.		0

#	Article	IF	Citations
73	Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease. , 2019, , 309-329.		0
74	Monogenic Glomerular Diseases. Nephrology Self-assessment Program: NephSAP, 2020, 19, 160-168.	3.0	0